Boan Biotech and Merck reached a strategic cooperation to build a "digital factory of the future"

Shanghai, November 24, 2021/PRNewswire/ - Luye Pharmaceutical Group's holding subsidiary Boan Biotech announced that it has signed a strategic cooperation memorandum with Merck, a world-leading technology company, and the two parties will carry out comprehensive cooperation to jointly promote Boan Biotech’s Construction of "Future Digital Factory"

With continuous technological innovation in the field of pharmaceutical production, digital transformation has gradually played an increasingly important role in the development of the biopharmaceutical industry

In order to accelerate the realization of this goal, Boan Biotech and Merck have established strategic partnerships in the following areas and continue to carry out comprehensive and in-depth cooperation, including: Bio4C? ProcessPad data collection visualization and analysis software platform, antibody enhancement process, continuous process equipment , affordable type of media development, cost analysis and process optimization solutions, consumables (including pre-market prototype) supply and demand forecast arrival in batches and other fields

Boan Bio is the first domestic pharmaceutical company to introduce the Bio4C® ProcessPad digital platform

“Boan Bio is committed to providing high-quality innovative biological drugs for patients in China and even around the world.

"The intelligentization of biopharmaceuticals is the future trend and direction

"We are very pleased to have reached a strategic cooperation with Boan Bio

Boan Biology is committed to becoming a "world's leading international biotechnology innovation enterprise", engaged in the development of biological products in China, the United States and the European Union